Sign In
Buy SAN
$14.10
-0.0100 (-0.0709%)
At Close: Jul 31, 2026
Communiqué de presse: La FDA accorde un examen prioritaire à Dupixent® (dupilumab) dans le traitement du prurigo nodulaire de l’adulte
05:00am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
La FDA accorde un examen prioritaire à Dupixent® (dupilumab) dans le traitement du prurigo nodulaire de l’adulte
Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial
05:30am, Monday, 30'th May 2022 GlobeNewswire Inc.
Update on Cialis® Rx-to-OTC Switch Actual Use Trial
Communiqué de presse: Point sur l’essai en condition réelle d’utilisation de Cialis® en vue de son transfert sur le marché de l'automédication
05:30am, Monday, 30'th May 2022 GlobeNewswire Inc.
Point sur l’essai en condition réelle d’utilisation de Cialis® en vue de son transfert sur le marché de l'automédication
3 Top Stocks to Buy From the Prospering Foreign Banks Industry
12:21pm, Friday, 27'th May 2022 Zacks Investment Research
Despite concerns related to higher restructuring costs and uneven economic growth, Zacks Foreign Banks industry stocks like UBS, Banco Santander (SAN) and Bancolombia (CIB) are poised to gain from int
3 Top Stocks to Buy From the Prospering Foreign Banks Industry
09:48am, Friday, 27'th May 2022
Despite concerns related to higher restructuring costs and uneven economic growth, Zacks Foreign Banks industry stocks like UBS, Banco Santander (SAN) and Bancolombia (CIB) are poised to gain from int
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
07:15pm, Friday, 20'th May 2022 GlobeNewswire Inc.
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
Communiqué de presse: La FDA approuve Dupixent® (dupilumab) – premier médicament pour le traitement de l’œsophagite à éosinophiles de l’adulte et de l’enfant à partir de 12 ans
07:15pm, Friday, 20'th May 2022 GlobeNewswire Inc.
La FDA approuve Dupixent® (dupilumab) – premier médicament pour le traitement de l’œsophagite à éosinophiles de l’adulte et de l’enfant à partir de 12 ans
Baron Fintech Fund Q1 2022 Shareholder Letter
04:55am, Wednesday, 18'th May 2022 Seeking Alpha
In the quarter ended March 31, 2022, Baron FinTech Fund (the “Fund”) fell 16.67% (Institutional Shares). Click here to read the full fund letter.
Implied Volatility Surging for Banco Santander (SAN) Stock Options
05:28pm, Tuesday, 17'th May 2022 Zacks Investment Research
Investors need to pay close attention to Banco Santander (SAN) stock based on the movements in the options market lately.
Is Banco Santander (SAN) a Great Value Stock Right Now?
01:40pm, Tuesday, 17'th May 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Is Banco Santander (SAN) a Great Value Stock Right Now?
11:17am, Tuesday, 17'th May 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Sarclisa® (isatuximab) en association permet d’obtenir un allongement sans précédent la survie médiane sans progression des patients atteints d’un myélome multiple en rechute traités par un
Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
07:30am, Sunday, 15'th May 2022 GlobeNewswire Inc.
Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
Is WisdomTree Europe Hedged Equity ETF (HEDJ) a Strong ETF Right Now?
10:20am, Wednesday, 11'th May 2022 Zacks Investment Research
Smart Beta ETF report for HEDJ
Communiqué de presse: De nouvelles analyses des données relatives au nirsevimab confortent son efficacité contre le VRS
06:00am, Wednesday, 11'th May 2022 GlobeNewswire Inc.
De nouvelles analyses des données relatives au nirsevimab confortent son efficacité contre le VRS
